Carlsmed, Inc. (CARL) Key Metrics
CARL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $366.1M
- Enterprise value
- $336.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 5.8
- Price / book
- 4.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
CARL key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCARL returns How much profit the business earns on the capital it uses.
CARL per-share figures Results divided by the shares outstanding at year-end.
CARL financial health Debt, liquidity and how easily interest is covered.
CARL efficiency & capital use Working capital cycle and where the cash goes.
CARL valuation history
CARL returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CARL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CARL price vs earnings per share
CARL key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $175.6M | — | — |
| Enterprise value | $83.3M | — | — |
| Price / sales | 3.5 | — | — |
| Price / book | 1.8 | — | — |
| EV / sales | 1.6 | — | — |
| Earnings yield | −16.9% | — | — |
| Free cash flow yield | −16.9% | — | — |
| Share price at fiscal year-end | $12.35 | — | — |
| Per share | |||
| Revenue per share | $3.55 | $1.64 | — |
| Earnings per share | −$2.08 | −$1.46 | — |
| Operating cash flow per share | −$2.04 | −$1.54 | — |
| Free cash flow per share | −$2.08 | −$1.55 | — |
| Cash per share | $7.72 | $2.42 | — |
| Book value per share | $6.95 | −$4.26 | — |
| Tangible book value per share | $6.95 | −$4.26 | — |
| Capex per share | $0.05 | $0.01 | — |
| Debt per share | $1.22 | $1.04 | — |
| Shares outstanding | 14.2M | 16.6M | — |
| Change in shares outstanding | −14.1% | — | — |
| Returns & profitability | |||
| Return on equity (ROE) | −209.9% | — | — |
| Return on assets (ROA) | −32.6% | −73.7% | −134.8% |
| Return on tangible assets | −22.8% | −46.8% | −134.8% |
| Free cash flow margin | −58.6% | −94.4% | −127.8% |
| Financial health | |||
| Total debt | $17.4M | $17.2M | $11.4M |
| Cash & short-term investments | $109.8M | $40.1M | $7.2M |
| Net debt | −$92.4M | −$22.9M | $4.2M |
| Debt / equity | 0.18 | — | — |
| Debt / assets | 0.13 | 0.33 | 0.81 |
| Current ratio | 8.87 | 5.60 | 1.58 |
| Quick ratio | 8.74 | 5.48 | 1.50 |
| Interest coverage | -21.4 | -18.3 | -29.0 |
| Working capital | $112.4M | $40.5M | $4.3M |
| Invested capital | $6.5M | −$93.6M | −$42.0M |
| Tangible asset value | $98.9M | −$70.6M | −$46.1M |
| Net current asset value | $95.4M | −$73.1M | −$48.4M |
| Graham net-net per share | $6.19 | −$4.63 | — |
| Capital allocation | |||
| Capex / revenue | 1.3% | 0.7% | 1.0% |
| Capex / depreciation | 2.28 | 1.24 | 0.99 |
| Stock-based compensation / revenue | 3.8% | 0.9% | 0.8% |
| R&D / revenue | 33.7% | 52.7% | 53.7% |
| SG&A / revenue | 102.1% | 109.9% | 153.1% |
| Efficiency | |||
| Days sales outstanding | 65.5 | 66.7 | 83.8 |
| Days of inventory on hand | 41.6 | 40.3 | 54.2 |
| Days payables outstanding | 100.9 | 105.3 | 159.6 |
| Cash conversion cycle (days) | 6.2 | 1.7 | -21.6 |
| Receivables turnover | 5.57 | 5.47 | 4.35 |
| Payables turnover | 3.62 | 3.47 | 2.29 |
| Inventory turnover | 8.78 | 9.07 | 6.74 |
| Asset turnover | 0.56 | 0.83 | 0.98 |
| Average receivables | $9.1M | $5.0M | $3.2M |
| Average payables | $3.4M | $2.1M | $1.7M |
| Average inventory | $1.4M | $785,000 | $575,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from CARL's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CARL valuation and financial ratios
Carlsmed earned a return on equity of −209.9% in fiscal 2025. It ended the year with $17.4 million of debt and $109.8 million in cash and short-term investments, a net cash position of $92.4 million.
See the CARL income statement, the CARL chart for price history, or the CARL stock overview for the latest quote and news.
CARL key metrics FAQ
What is Carlsmed's return on equity?
Carlsmed's return on equity (ROE) was −209.9% in fiscal 2025: net income of -$29.6 million on average shareholders' equity of $14.1 million.
How much debt does Carlsmed have?
Carlsmed had total debt of $17.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.18 and more cash than debt.
What is Carlsmed's free cash flow yield?
Carlsmed generated -$29.6 million of free cash flow in fiscal 2025, a free cash flow yield of −16.9% on its market value at year-end ($175.6 million).
What is Carlsmed's current ratio?
Carlsmed's current ratio was 8.87 at the end of fiscal 2025: current assets were 8.87 times current liabilities.